Sign In
Buy SNY
$43.98
-0.680 (-1.52%)
At Close: Jul 20, 2026
Enable Injections Announces $30 Million Investment from Sanofi to Accelerate Manufacturing Capabilities
07:30am, Tuesday, 06'th Jan 2026
CINCINNATI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”) a healthcare innovation company developing and manufacturing the enFuse® On-Body Delivery System (OBDS), announce
FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children
11:26am, Monday, 05'th Jan 2026
Sanofi wins FDA priority review to expand Tzield's use to children as young as one, aiming to delay type 1 diabetes progression.
Sanofi Says FDA Agrees to Review Diabetes Drug Age Range
01:40am, Monday, 05'th Jan 2026
The company said the regulator accepted a priority review to potentially expand the current age range for its Tzield type-1 diabetes drug to include children as young as one year old.
Press Release: Sanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes
01:00am, Monday, 05'th Jan 2026
Sanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes If approved, Tzield would be the first disease-modifying therapy to delay the onset of stage 3 T1
NEW YORK and NEW ORLEANS, Dec. 30, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Traders Buy High Volume of Sanofi Put Options (NASDAQ:SNY)
01:51am, Tuesday, 30'th Dec 2025
Sanofi (NASDAQ: SNY - Get Free Report) saw some unusual options trading activity on Monday. Stock traders acquired 14,850 put options on the company. This is an increase of approximately 370% compared
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
FDA Issues CRL to SNY's Regulatory Filing for Multiple Sclerosis Drug
12:26pm, Wednesday, 24'th Dec 2025
Sanofi receives an FDA CRL for tolebrutinib in nrSPMS after multiple review extensions. The EC clears Wayrilz for treating immune thrombocytopenia.
Sanofi to Acquire Dynavax, Expanding Vaccine Portfolio
12:14pm, Wednesday, 24'th Dec 2025
Sanofi (SNY) has announced an agreement to acquire Dynavax (DVAX) for $15.50 per share, valuing the deal at approximately $2.2 billion. This acquisition will en
Sanofi to Acquire Dynavax for $2.2 Billion, Expanding Vaccine Portfolio
11:24am, Wednesday, 24'th Dec 2025
Sanofi (SNY, Financials) stated on Wednesday that it would buy Dynavax Technologies for around $2.2 billion, or $15.50 per share in cash. This is a 39% premium
Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise
11:01am, Wednesday, 24'th Dec 2025
SNY's $2.2 billion deal for Dynavax adds Heplisav-B, a shingles candidate, and other vaccine programs, strengthening its adult vaccine franchise and pipeline.
Sanofi to acquire Dynavax in $2.2B Deal to boost adult vaccines
09:41am, Wednesday, 24'th Dec 2025
French pharmaceutical giant Sanofi SA said on Wednesday it has agreed to acquire US-based vaccines company Dynavax Technologies Corp in a $2.2 billion deal, strengthening its presence in the adult imm
This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion.
07:59am, Wednesday, 24'th Dec 2025
Sanofi agrees to acquire Dynavax Technologies in an all-cash deal worth $2.2 billion in total equity value.
Biggest Mover Wednesday: Dynavax Stock Soars on $2.2 billion Acquisition Deal
07:43am, Wednesday, 24'th Dec 2025
Shares of Dynavax Technologies (DVAX) surged about 37% on early Wednesday after French drugmaker Sanofi (SNY) agreed to buy the U.S. vaccine company in a cash d
Sanofi to acquire Dynavax for $2.2B, sending shares higher by 37%
06:49am, Wednesday, 24'th Dec 2025
Shares of Dynavax Technologies jumped sharply in premarket trading on Wednesday after the US vaccine maker agreed to be acquired by French pharmaceutical group Sanofi in an all-cash deal valued at abo
